Nippon Chemiphar Co., Ltd. (4539) AI Stock Analysis

• Market Cap: ¥6.22B
• Dividend Yield: 3.21%
• Average Volume (3M): 2.30K
• Price to Earnings (P/E): 11.6
• Beta (1Y): 0.27
• Revenue Growth: 4.25%
• EPS Growth: N/A
• Country: JP
• Employees: 887
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 34.21
• Shares Outstanding: 4,261,420
• 10 Day Avg. Volume: 1,680
• 30 Day Avg. Volume: 2,300
• PEG Ratio: -0.07
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.16
• P/FCF Ratio: -2.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ¥1,841.00 ▲(16.15% Upside)
• Action: Reiterated Date: 11/05/25
• Date: Action: Reiterated 11/05/25

Nippon Chemiphar's overall stock score reflects a balanced view of its financial performance and valuation. While the company shows potential with improved profitability and a stable balance sheet, ongoing cash flow challenges and weak technical indicators weigh on the score. The reasonable valuation and attractive dividend yield are positive factors.

Positive Factors

Balance sheet health

A debt-to-equity near 0.94 and an equity ratio around 38.5% indicate manageable leverage and a solid capital base. This structure supports funding of R&D and manufacturing needs, cushions regulatory or product-cycle shocks, and preserves strategic flexibility over the medium term.

Negative Factors

Negative free cash flow

Persistently negative operating and free cash flow shows difficulty converting accounting profits into cash. This stresses liquidity, limits ability to fund R&D, capex, or dividends internally, and may force external financing or asset adjustments, posing a structural risk over coming months.

Nippon Chemiphar Co., Ltd. Business Overview & Revenue Model

Company Description

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic...

Read more

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic...

How the Company Makes Money

The company makes money primarily by selling pharmaceutical products in Japan. Its core revenue stream is sales of prescription drugs, where revenue is generated when products are shipped to wholesalers and/or medical-market channels and ultimatel...

Read more

The company makes money primarily by selling pharmaceutical products in Japan. Its core revenue stream is sales of prescription drugs, where revenue is generated when products are shipped to wholesalers and/or medical-market channels and ultimatel...

Nippon Chemiphar Co., Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	32.82B	32.57B	30.75B	31.56B	32.51B	31.54B
Gross Profit	8.93B	8.75B	7.74B	8.19B	9.07B	11.44B
EBITDA	2.01B	1.83B	1.40B	2.10B	2.68B	2.23B
Net Income	395.00M	294.00M	-180.00M	339.00M	700.00M	495.00M
Balance Sheet
Total Assets	52.68B	49.85B	49.55B	48.57B	49.45B	47.12B
Cash, Cash Equivalents and Short-Term Investments	9.69B	7.02B	9.20B	10.53B	11.64B	10.58B
Total Debt	19.02B	18.06B	16.98B	15.23B	14.79B	15.37B
Total Liabilities	33.76B	30.68B	31.08B	30.03B	30.95B	29.11B
Stockholders Equity	18.92B	19.17B	18.46B	18.53B	18.50B	18.01B
Cash Flow
Free Cash Flow	0.00	-1.86B	-2.34B	-1.93B	1.07B	-85.00M
Operating Cash Flow	0.00	-265.00M	296.00M	-916.00M	1.80B	1.50B
Investing Cash Flow	0.00	-1.66B	-3.14B	-394.00M	35.00M	-1.02B
Financing Cash Flow	0.00	-305.00M	1.45B	144.00M	-793.00M	29.00M

Nippon Chemiphar Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1585.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4539, the sentiment is Positive. The current price of 1585 is below the 20-day moving average (MA) of 1707.13, below the 50-day MA of 1698.72, and above the 200-day MA of 1563.61, indicating a bullish trend. The MACD of 11.46 indicates Negative momentum. The RSI at 51.93 is Neutral, neither overbought nor oversold. The STOCH value of 46.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4539.

Nippon Chemiphar Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4574	66 Neutral	¥15.07B	16.22	―	―	-5.41%	―
4539	64 Neutral	¥6.22B	11.64	―	3.21%	4.25%	―
4577	63 Neutral	¥43.45B	18.30	―	2.75%	7.56%	-48.91%
4524	62 Neutral	¥9.04B	15.24	―	2.55%	3.23%	42.87%
4538	60 Neutral	¥20.62B	5.79	―	3.71%	7.50%	-281.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4512	48 Neutral	¥12.08B	7.11	―	1.06%	5.42%	-62.03%